Adaptive Biotechnologies (ADPT) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adaptive Biotechnologies (ADPT) has outperformed Tarsus Pharmaceuticals (TARS) over the past year, gaining 83.1% versus a gain of 7.6%. Over five years, TARS leads with a +158.1% price change compared with -21.6% for ADPT. Adaptive Biotechnologies is the larger company by market cap ($4.16 billion vs $3.38 billion), about 1.2 times the size, while Tarsus Pharmaceuticals is growing revenue faster (+146.7% vs +54.8%).
Tarsus Pharmaceuticals converts more of its revenue into profit, with a net margin of -14.7% versus -21.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADPT | TARS |
|---|---|---|
| Share price | $26.09 | $72.22 |
| Market cap | $4.16B | $3.38B |
| 1-day change | -0.72% | -1.89% |
| YTD return | +61.82% | -10.10% |
| 1-year return | +83.14% | +7.59% |
| 5-year return | -21.55% | +158.10% |
| EPS (TTM) | $-0.41 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $276.98M | $451.36M |
| Revenue growth (YoY) | +54.77% | +146.71% |
| Net income (latest FY) | $-59.50M | $-66.42M |
| Gross margin | 74.24% | — |
| Operating margin | -20.62% | -15.72% |
| Net margin | -21.48% | -14.72% |
| 52-week high | $30.74 | $91.53 |
| 52-week low | $12.00 | $53.89 |
| Distance from 52-week high | -15.13% | -21.10% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +8.51% | +37.77% |
| Average volume | 2.38M | 894.35K |
| Shares outstanding | 159.60M | 46.79M |
| Employees | 624 | 370 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADPT has outperformed TARS by 75.6 percentage points over the past year.
- Tarsus Pharmaceuticals is more profitable, keeping -14.7 cents of every revenue dollar as net income versus -21.5 cents for Adaptive Biotechnologies.
- Tarsus Pharmaceuticals grew revenue faster in its latest fiscal year (+146.71% vs +54.77%).
About Adaptive Biotechnologies
ADPT stock →Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
ADPT vs TARS FAQ
Which is bigger, Adaptive Biotechnologies or Tarsus Pharmaceuticals?
Adaptive Biotechnologies (ADPT) is larger, with a market capitalization of $4.16B compared with $3.38B for Tarsus Pharmaceuticals (TARS).
Which stock has performed better over the past year, ADPT or TARS?
ADPT returned +83.14% over the past 12 months, compared with +7.59% for TARS (price return, excluding dividends). Past performance does not predict future results.
Are Adaptive Biotechnologies and Tarsus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.